Response to " Ipilimumab (Yervoy) and the TGN1412 catastrophe"

Immunobiology

Volumn 217, Issue 6, 2012, Pages 590-592

  Curran, Michael A ^a   Callahan, Margaret K ^a   Subudhi, Sumit K ^a   Allison, James P ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c Ludwig Center for Cancer Immunotherapy   (United States)

Author keywords

CD28; CTLA 4; Ipilimumab

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; TGN 1412;

CARDIOGENIC SHOCK; COLITIS; CYTOKINE STORM; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LETTER; MELANOMA; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; IMMUNIZATION, PASSIVE; MELANOMA; SKIN NEOPLASMS;

EID: 84860234605     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.11.001     Document Type: Letter

References (7)

1. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
2. Kocak E., et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006, 66:7276-7284.
3. Kolar P., et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum. 2009, 60:123-132.
4. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
5. Sarnaik A.A., et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 2011, 17:896-906.
6. Simmons A.D., et al. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol. Immunother. 2008, 57:1263-1270.
7. Wing K., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.